Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF; Italian Headache Registry (RICe) Study Group.
Caponnetto V, et al. Among authors: rainero i.
CNS Drugs. 2023 Dec;37(12):1069-1080. doi: 10.1007/s40263-023-01050-3. Epub 2023 Nov 24.
CNS Drugs. 2023.
PMID: 37999868
Free PMC article.
BACKGROUND: Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up. OBJECTIVE: We aimed to evaluate the long-term (up to 52 weeks) effectiveness and tolerability of fremane …
BACKGROUND: Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few …